DOCSLIB.ORG

Chemical Applications in Anti Fungal Agents and Classification of Fungal Infections

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Chemical Applications in Anti Fungal Agents and Classification of Fungal Infections Vol 11, Issue 3, MARCH/ 2020 ISSN NO: 0377-9254 CHEMICAL APPLICATIONS IN ANTI FUNGAL AGENTS AND CLASSIFICATION OF FUNGAL INFECTIONS K.Priyanka ,S.Udhayalaxmi,K.Ravi Kiran Departmentof Chemistry, Nizam College, Osmania University, Hyderabad-500001 [email protected] Fungal infections are common Abstract - Oropharyngeal Histoplasmosi in human beings and animals. The recent candidiasis s Tinea development of novel antifungal agents as and Tinea unguium significantly contributed to the successful capitis treatment of fungal dieases.Most of these agents are fungistatic and do not kill the Anti fungal agents used for fungal cell. Thus facilitating the emergency of resistance species, which further treatment of some Paediatric complicate therapy.Alternatively, some of infections the most effective anti fungal agents are too toxic after continuous use or can only be Candida diaper dermatitis (CDD) administered intravenously. The ideal antifungal drug would be non toxic, Candida Diaper Candidiasis is general term fungicidal, and amenable to self describing any of a number of inflammatory administration. Anti fungal agents have skin conditions that can occur in the diaper wider range of applications. area. CDD is common during the second to Keywords: Antifungal agents, fungicidal, fourth months of life in healthy infants. One candidiasis, Topical medications, hundred present of the newborn infants and Seborrhotic dermatitis. 88% of the older children who suffered from candidal diaper rashes harbored Candida Introduction albicans in the intestine. Candida albicans is present in the feces of 90% of such An antifungal agent is a drug which infants. selectively kills fungal pathogen with minimal toxicity to the host. This chapter Topical antifungal therapy is also necessary. summarizes the general applications of Miconazole ointment with zinc oxide antifungal agents. Novel antifungal drug petroleum base was safe and effective, anti (NB-002) developed recently for topical fungal drug. Ointments, creams and powders applications in humans. The incidence of of nystatin, miconazole and clotrimazole are fungal infections increases with increase in available. It is still not clear whether antibiotic usage and increase in immune concomitant oral and topical antifungal suppressed populations. should be recommended. Some anti- inflammatory preparations are used to Paediatric Animal Topical treatment of CDD. infections infections infections Candida Pityriasis Cryptococcosi Mucocutaneous candidiasis diaper versicolo s dermatitis r Mucocutaneous candidiasis is common and Tinea is an immune disorder of T cell it is Mucocutaneou pedis Aspergillisis persistant super ficial infections of the skin, s candidiasis mucous membrane, and nails. www.jespublication.com Page No:981 Vol 11, Issue 3, MARCH/ 2020 ISSN NO: 0377-9254 Mucocutaneous candidiasis is caused by Second-generation imidazoles, such as Candida organism usually Candida albicans. fluconazole and itraconazole or other new oral anti fungal agents Nystain oral Anti fungal agents such as clotrimazole, suspensions. ketoconazole, itraconazole, and fluconazole are dramatic improvement in the treatment SEBORRHEIC DERMATITIS of all forms of CMCs. However, following the use of these drugs. albicans strains Seborrhea dermatitis is the most common resistant to azole antifungal drugs have been paediatric superficial dermatophyte subsequently isolated requiring novel infection. Seborrhea dermatitis is also therapeutic agents. These include called as tinea capitis. tinea capitis does not flucytosine, amphotericin B, the newest respond well to topical therapy alone, oral azoles and, more recently, echinocandins. therapy is required Seborrhea dermatitis and pityriasis capitis (cradle cap) are common, Thrush but usually mild, scalp infections caused by Malassezia species (eg, Malassezia furfur). Candidiasis of the mouth and throat, also known as thrush or oropharyngeal The condition often resolves with mild soap candidiasis.Oropharyngeal candidiasis application. Shampoos containing selenium (thrush) is one of the paediatric infections. sulfide are useful in severe forms. antifungal This is mainly effect the infants. medications, such as ketoconazole, Oropharyngeal candidiasis (thrush) may itraconazole, terbinafine, and fluconazole, have been reported as effective alternative start as early as seven days after birth. therapeutic agents for tinea capitis. Of these agents, itraconazole and terbinafine are used Prescription treatment such as oral most commonly. fluconazole, clotrimazole troches or nystain suspension usually provides effective Anti fungal agents used for treatment for oropharyngeal candidiasis. treatment of some animal infections Generally some oldest therapeutic agents Cryptococcosis and some anti fungal agents are used for treatment of Oropharyngeal candidiasis. The Cryptococcosis is a fungal disease that oldest therapeutic agent, is Topical gentian affects the respiratory tract, eyes, skin, and violet, it is moderately effective against central nervous system of dogs. thrush but it is prolonged use can cause irritation and nausea.Nystain, Fluconazole, The drug of choice for initial therapy in Clotrimazole, imidazole, and ketoconazole CNS cryptococcosis is amphotericin B. It are anti fungal agents. Latest anti fungal may be used alone or in combination with agent imidazole is divided in two types First flucytosine.Ketoconazole, itraconazole or generation of imidazole and second fluconazole have also been successful as generation of imidazole. treatment. Other drugs also used that are amphotericinB include amphotericine B The first-generation imidazoles, such as lipid complex, amphotericine B choleseryl miconazole and clotrimazole, are effective complex and, amphotericine B colloidal drugs. However, miconazole gel and oral dispersion. preparation of clotrimazole are not licensed in Canada. Chronic oral candidiasis can Aspergillosis respond to clotrimazole troches. Aspergillosis is a fungal infection seen in mostly young dogs that affects the long www.jespublication.com Page No:982 Vol 11, Issue 3, MARCH/ 2020 ISSN NO: 0377-9254 nose. Aspergillosis is the name given to a Topical anti fungal agents are used to treat wide variety of diseases caused by infection active Pityriasis versicolor. They are by fungi of the genus Aspergillus. The most include, 1)Propylene glycol 2)sodium thio common cause is Aspergillus fumigatus. sulphate solutions 3)selenium sulfide 4)Terbinafine gel 5)ciclopirox 6)topical Anti fungal drugs such as voriconazole and azoles including clotrimazole liposomal amphotericin B are used for treat miconazole,ketoconazole.Antifungal aspergillosis diseases. Other drugs used, preparations can be effective, but such as amphotericin recurrences are common Topical B, caspofungin ,flucytosine , ketoconazole, selenium sulfide and itraconazole, are used to treat this fungal clotrimazole are the most common infection. However, a growing proportion of treatments. infections are resistant to the triconazoles drugs are resistance to growth of Aspergillus fumigates. TINEA PEDIS Histoplasmosis Athlete’s foot is a common superficial Histoplasmosis is an infection that occurs fungal infection of the foot. The medical term from breathing in the spores of the fungus is tinea pedis. Causes include T rubrum, T Histoplasma capsulatum. It is primarily mentagro-phytes and E floccosum. This is affect the lungs. Bird, chicken and bat uncommon in young children. manure provide a rich environment for the fungus, but other origins have recently been Antifungal powders or creams can help reported. Antifungal agents usage, control the infection. These generally depending on the form or stage of disease contain miconazole, clotrimazole, or .Sometimes, long-term treatment with tolnaftate. Keep using the medicine for 1 - 2 antifungal drugs may be needed. weeks after the infection has cleared to prevent the infection from returning. Antifungal medications are used to treat severe cases of acute histoplasmosis and all If athlete's foot does not get better in 2-4 cases of chronic conditions. Typical weeks with self-care, or frequently returns, treatment of severe disease first involves see your health care provider. The health treatment with amphotericin B, followed by care provider may prescribe stronger oral itraconazole.Treatment with antifungal medications, such as itraconazole will need to continue for at ketoconazole or terbinafine. least a year in milder cases, and also oral itraconazole or ketoconazole is sufficient. Tinea unguium Tinea unguium is also called as fungal nail Anti fungal agents used for infection or Onychomycosis. .This nail treatment of Topical infections infection caused by fungi. such as various fungi species of Trichophyton and PITYRIASIS VERSICOLOR occasionally by candida albicans.Generally ointments and creams are used to treat tinea Pityriasis versicolor is a common infection unguium.In last stage of this infection of healthy people caused by a fungus that is creams and ointments generally do not help commonly found on normal human skin. cure the infection. Pityriasis versicolor is caused by Yeast of Latest anti fungal drugs such as the genus Malassezia, which may also be Fluconazole griseofulvin, terbinafine, found on normal skin. www.jespublication.com Page No:983 Vol 11, Issue 3, MARCH/ 2020 ISSN NO: 0377-9254 and itraconazole are used to treat this Infect Dis J. 1988; 7:303. condition. 9.Patterson TF. Aspergillus species. In: Mandell GL, Bennett JE, Dolin R, CONCLUSION eds. Principles
Load more

Recommended publications
  • Candida Auris
    microorganisms Review Candida auris: Epidemiology, Diagnosis, Pathogenesis, Antifungal Susceptibility, and Infection Control Measures to Combat the Spread of Infections in Healthcare Facilities Suhail Ahmad * and Wadha Alfouzan Department of Microbiology, Faculty of Medicine, Kuwait University, P.O. Box 24923, Safat 13110, Kuwait; [email protected] * Correspondence: [email protected]; Tel.: +965-2463-6503 Abstract: Candida auris, a recently recognized, often multidrug-resistant yeast, has become a sig- nificant fungal pathogen due to its ability to cause invasive infections and outbreaks in healthcare facilities which have been difficult to control and treat. The extraordinary abilities of C. auris to easily contaminate the environment around colonized patients and persist for long periods have recently re- sulted in major outbreaks in many countries. C. auris resists elimination by robust cleaning and other decontamination procedures, likely due to the formation of ‘dry’ biofilms. Susceptible hospitalized patients, particularly those with multiple comorbidities in intensive care settings, acquire C. auris rather easily from close contact with C. auris-infected patients, their environment, or the equipment used on colonized patients, often with fatal consequences. This review highlights the lessons learned from recent studies on the epidemiology, diagnosis, pathogenesis, susceptibility, and molecular basis of resistance to antifungal drugs and infection control measures to combat the spread of C. auris Citation: Ahmad, S.; Alfouzan, W. Candida auris: Epidemiology, infections in healthcare facilities. Particular emphasis is given to interventions aiming to prevent new Diagnosis, Pathogenesis, Antifungal infections in healthcare facilities, including the screening of susceptible patients for colonization; the Susceptibility, and Infection Control cleaning and decontamination of the environment, equipment, and colonized patients; and successful Measures to Combat the Spread of approaches to identify and treat infected patients, particularly during outbreaks.
    [Show full text]
  • A Fresh Look at Echinocandin Dosing
    J Antimicrob Chemother 2018; 73 Suppl 1: i44–i50 doi:10.1093/jac/dkx448 We can do better: a fresh look at echinocandin dosing Justin C. Bader1, Sujata M. Bhavnani1, David R. Andes2 and Paul G. Ambrose1* 1Institute for Clinical Pharmacodynamics (ICPD), Schenectady, NY, USA; 2University of Wisconsin, Madison, WI, USA *Corresponding author. Institute for Clinical Pharmacodynamics (ICPD), 242 Broadway, Schenectady, NY 12305, USA. Tel: !1-518-631-8101; Fax: !1-518-631-8199; E-mail: [email protected] First-line antifungal therapies are limited to azoles, polyenes and echinocandins, the former two of which are associated with high occurrences of severe treatment-emergent adverse events or frequent drug interactions. Among antifungals, echinocandins present a unique value proposition given their lower rates of toxic events as compared with azoles and polyenes. However, with the emergence of echinocandin-resistant Candida species and the fact that a pharmacometric approach to the development of anti-infective agents was not a main- stream practice at the time these agents were developed, we question whether echinocandins are being dosed optimally. This review presents pharmacokinetic/pharmacodynamic (PK/PD) evaluations for approved echino- candins (anidulafungin, caspofungin and micafungin) and rezafungin (previously CD101), an investigational agent. PK/PD-optimized regimens were evaluated to extend the utility of approved echinocandins when treating patients with resistant isolates. Although the benefits of these regimens were apparent, it was also clear that anidulafungin and micafungin, regardless of dosing adjustments, are unlikely to provide therapeutic exposures sufficient to treat highly resistant isolates. Day 1 probabilities of PK/PD target attainment of 5.2% and 85.1%, respectively, were achieved at the C.
    [Show full text]
  • The Impact of Lemongrass, Oregano, and Thyme Essential Oils on Candida Albicans’
    Walden University ScholarWorks Walden Dissertations and Doctoral Studies Walden Dissertations and Doctoral Studies Collection 2018 The mpI act of Lemongrass, Oregano, and Thyme Essential Oils on Candida albicans' Virulence Factors Jennifer Marie Eddins Walden University Follow this and additional works at: https://scholarworks.waldenu.edu/dissertations Part of the Alternative and Complementary Medicine Commons, Microbiology Commons, and the Public Health Education and Promotion Commons This Dissertation is brought to you for free and open access by the Walden Dissertations and Doctoral Studies Collection at ScholarWorks. It has been accepted for inclusion in Walden Dissertations and Doctoral Studies by an authorized administrator of ScholarWorks. For more information, please contact [email protected]. Walden University College of Health Sciences This is to certify that the doctoral dissertation by Jennifer M. Eddins has been found to be complete and satisfactory in all respects, and that any and all revisions required by the review committee have been made. Review Committee Dr. Aimee Ferraro, Committee Chairperson, Public Health Faculty Dr. Angela Prehn, Committee Member, Public Health Faculty Dr. Jagdish Khubchandani, University Reviewer, Public Health Faculty Chief Academic Officer Eric Riedel, Ph.D. Walden University 2018 Abstract The Impact of Lemongrass, Oregano, and Thyme Essential Oils on Candida albicans’ Virulence Factors by Jennifer M. Eddins BS, Colorado State University, 1989 Dissertation Submitted in Partial Fulfillment
    [Show full text]
  • Updates in Ocular Antifungal Pharmacotherapy: Formulation and Clinical Perspectives
    Current Fungal Infection Reports (2019) 13:45–58 https://doi.org/10.1007/s12281-019-00338-6 PHARMACOLOGY AND PHARMACODYNAMICS OF ANTIFUNGAL AGENTS (N BEYDA, SECTION EDITOR) Updates in Ocular Antifungal Pharmacotherapy: Formulation and Clinical Perspectives Ruchi Thakkar1,2 & Akash Patil1,2 & Tabish Mehraj1,2 & Narendar Dudhipala1,2 & Soumyajit Majumdar1,2 Published online: 2 May 2019 # Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Purpose of Review In this review, a compilation on the current antifungal pharmacotherapy is discussed, with emphases on the updates in the formulation and clinical approaches of the routinely used antifungal drugs in ocular therapy. Recent Findings Natamycin (Natacyn® eye drops) remains the only approved medication in the management of ocular fungal infections. This monotherapy shows therapeutic outcomes in superficial ocular fungal infections, but in case of deep-seated mycoses or endophthalmitis, successful therapeutic outcomes are infrequent, as a result of which alternative therapies are sought. In such cases, amphotericin B, azoles, and echinocandins are used off-label, either in combination with natamycin or with each other (frequently) or as standalone monotherapies, and have provided effective therapeutic outcomes. Summary In recent times, amphotericin B, azoles, and echinocandins have come to occupy an important niche in ocular antifungal pharmacotherapy, along with natamycin (still the preferred choice in most clinical cases), in the management of ocular fungal infections.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • In Vitro Synergistic Interactions of Isavuconazole and Echinocandins Against Candida Auris
    antibiotics Article In Vitro Synergistic Interactions of Isavuconazole and Echinocandins against Candida auris Unai Caballero 1, Sarah Kim 2 , Elena Eraso 3 , Guillermo Quindós 3 , Valvanera Vozmediano 2, Stephan Schmidt 2 and Nerea Jauregizar 1,* 1 Department of Pharmacology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain; [email protected] 2 Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, FL 32827, USA; [email protected]fl.edu (S.K.); [email protected]fl.edu (V.V.); [email protected]fl.edu (S.S.) 3 Department of Immunology, Microbiology and Parasitology, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), 48940 Leioa, Spain; [email protected] (E.E.); [email protected] (G.Q.) * Correspondence: [email protected] Abstract: Candida auris is an emergent fungal pathogen that causes severe infectious outbreaks globally. The public health concern when dealing with this pathogen is mainly due to reduced susceptibility to current antifungal drugs. A valuable alternative to overcome this problem is to investigate the efficacy of combination therapy. The aim of this study was to determine the in vitro interactions of isavuconazole with echinocandins against C. auris. Interactions were determined using a checkerboard method, and absorbance data were analyzed with different approaches: the fractional inhibitory concentration index (FICI), Greco universal response surface approach, and Bliss interaction model. All models were in accordance and showed that combinations of isavu- conazole with echinocandins resulted in an overall synergistic interaction. A wide range of concen- Citation: Caballero, U.; Kim, S.; Eraso, trations within the therapeutic range were selected to perform time-kill curves.
    [Show full text]
  • Anidulafungin Versus Caspofungin for the Treatment of Proven Invasive Candidiasis; a Retrospective Comparative Study
    P2367 Anidulafungin versus caspofungin for the treatment of proven invasive candidiasis; a retrospective comparative study Reem Almaghrabi1, Abeer Al-jomaiah*2, Noha Mukhtar2, Wafa Alfahad3, Nisreen Al Sherbini4, Abeer Albaadani4, Ali Omrani2 1king faisal specialist hospital and research centre, medicine, riyadh, Saudi Arabia, 1king faisal specialist hospital and research centre, medicine, riyadh, Saudi Arabia, 3Prince Sultan Military Hospital , Pharamacy, Riyadh, Saudi Arabia, 4Prince Sultan Military Hospital , Medicine, Riyadh, Saudi Arabia Background: Invasive candidiasis (IC) is associated with considerable morbidity and mortality. The comparative efficacy of caspofungin compared with anidulafungin in the treatment of IC has not been reported. The aim of this study was to compare the clinical and microbiological outcomes of caspofungin and anidulafungin in the treatment of IC in Saudi Arabia. Methods: Retrospective, multicentre, cohort study of patients aged ≥18 years with microbiologically proved IC who received systemic caspofungin or anidulafungin for ≥ 5 days. Patients who received systemic amphotericin B or micafungin within the preceding 14 days were excluded. The primary endpoint was mortality at the end of IV antifungal therapy. Analyses were performed using IBM SPSS for Windows. Results: A total of 123 patients were included, 111 patients in the caspofungin group and 21 in the anidulafungin group. Significantly more patients with diabetes mellitus received anidulafungin while more patient on immunosuppressive therapy were in the caspofungin arm. There were no other significant differences in baseline characteristics between the two groups (Table 1). The median duration of therapy was 18 days for caspofungin and 19 days for anidulafungin group (p 0.23). Mortality at the end of antifungal therapy was observed in 41 (36.9%) in the caspofungin group compared with 11 (55%) in the anidulafungin group (P 0.23).
    [Show full text]
  • Estonian Statistics on Medicines 2013 1/44
    Estonian Statistics on Medicines 2013 DDD/1000/ ATC code ATC group / INN (rout of admin.) Quantity sold Unit DDD Unit day A ALIMENTARY TRACT AND METABOLISM 146,8152 A01 STOMATOLOGICAL PREPARATIONS 0,0760 A01A STOMATOLOGICAL PREPARATIONS 0,0760 A01AB Antiinfectives and antiseptics for local oral treatment 0,0760 A01AB09 Miconazole(O) 7139,2 g 0,2 g 0,0760 A01AB12 Hexetidine(O) 1541120 ml A01AB81 Neomycin+Benzocaine(C) 23900 pieces A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+Thymol(dental) 2639 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+Cetylpyridinium chloride(gingival) 179340 g A01AD81 Lidocaine+Cetrimide(O) 23565 g A01AD82 Choline salicylate(O) 824240 pieces A01AD83 Lidocaine+Chamomille extract(O) 317140 g A01AD86 Lidocaine+Eugenol(gingival) 1128 g A02 DRUGS FOR ACID RELATED DISORDERS 35,6598 A02A ANTACIDS 0,9596 Combinations and complexes of aluminium, calcium and A02AD 0,9596 magnesium compounds A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 591680 pieces 10 pieces 0,1261 A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 1998558 ml 50 ml 0,0852 A02AD82 Aluminium aminoacetate+Magnesium oxide(O) 463540 pieces 10 pieces 0,0988 A02AD83 Calcium carbonate+Magnesium carbonate(O) 3049560 pieces 10 pieces 0,6497 A02AF Antacids with antiflatulents Aluminium hydroxide+Magnesium A02AF80 1000790 ml hydroxide+Simeticone(O) DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 34,7001 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 3,5364 A02BA02 Ranitidine(O) 494352,3 g 0,3 g 3,5106 A02BA02 Ranitidine(P)
    [Show full text]
  • 1 in Vitro and in Vivo Interaction of Caspofungin with Isavuconazole Against Candida Auris
    bioRxiv preprint doi: https://doi.org/10.1101/2021.03.08.434267; this version posted March 8, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 In vitro and in vivo interaction of caspofungin with isavuconazole against Candida auris 2 planktonic cells and biofilms 3 4 5 Short title: Isavuconazole with caspofungin against C. auris 6 7 Fruzsina Nagy1,2, Zoltán Tóth1,2,3, Fanni Nyikos1, Lajos Forgács1,2, Ágnes Jakab4, Andrew M. 8 Borman5,6, László Majoros1, Renátó Kovács1,7* 9 10 1 Department of Medical Microbiology, Faculty of Medicine, University of Debrecen, 4032 11 Debrecen, Nagyerdei krt. 98., Hungary 12 2 Doctoral School of Pharmaceutical Sciences, University of Debrecen, Nagyerdei krt. 98, 13 4032 Debrecen, Hungary 14 3 Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, University of 15 Debrecen, Nagyerdei krt. 98, 4032 Debrecen, Hungary 16 4 Department of Molecular Biotechnology and Microbiology, Faculty of Science and 17 Technology, Institute of Biotechnology, University of Debrecen, Debrecen, Hungary. 18 5 UK National Mycology Reference Laboratory, Public Health England, Science Quarter, 19 Southmead Hospital, Bristol BS10 5NB, UK 20 6 Medical Research Council Centre for Medical Mycology, University of Exeter, Exeter EX4 21 4QD, UK 22 7 Department of Metagenomics, University of Debrecen, Nagyerdei krt. 98, 4032 Debrecen, 23 Hungary 24 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.03.08.434267; this version posted March 8, 2021.
    [Show full text]
  • Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies
    Arrhythmogenic potential of drugs FP7-HEALTH-241679 http://www.aritmo-project.org/ Common Study Protocol for Observational Database Studies WP5 – Analytic Database Studies V 1.3 Draft Lead beneficiary: EMC Date: 03/01/2010 Nature: Report Dissemination level: D5.2 Report on Common Study Protocol for Observational Database Studies WP5: Conduct of Additional Observational Security: Studies. Author(s): Gianluca Trifiro’ (EMC), Giampiero Version: v1.1– 2/85 Mazzaglia (F-SIMG) Draft TABLE OF CONTENTS DOCUMENT INFOOMATION AND HISTORY ...........................................................................4 DEFINITIONS .................................................... ERRORE. IL SEGNALIBRO NON È DEFINITO. ABBREVIATIONS ......................................................................................................................6 1. BACKGROUND .................................................................................................................7 2. STUDY OBJECTIVES................................ ERRORE. IL SEGNALIBRO NON È DEFINITO. 3. METHODS ..........................................................................................................................8 3.1.STUDY DESIGN ....................................................................................................................8 3.2.DATA SOURCES ..................................................................................................................9 3.2.1. IPCI Database .....................................................................................................9
    [Show full text]
  • The Use of Antifungal Therapy in Neonatal Intensive Care
    The Use of Antifungal Therapy in Neonatal Intensive Care a a,b Daniela Testoni, MD , P. Brian Smith, MD, MHS, MPH , a,b, Daniel K. Benjamin Jr, MD, PhD, MPH * KEYWORDS Invasive candidiasis Amphotericin B deoxycholate Flucytosine Fluconazole Voriconazole Posaconazole Micafungin Anidulafungin Caspofungin Invasive candidiasis in extremely premature infants is the second most common cause of infectious disease-related death.1 Birth weight is strongly related to the inci- dence of invasive candidiasis (1% of infants born weighing 1000–1500 g vs up to 12% of infants born weighing 401–750 g).2 The morbidity and mortality of premature infants with invasive candidiasis are high.3,4 In a cohort of 320 extremely-low-birth-weight (ELBW, <1000 g birth weight) infants with invasive candidiasis, 73% died or were neu- rodevelopmentally impaired at 18 to 22 months’ corrected age.3 A unique characteristic of invasive candidiasis in infants is the frequent involvement of the central nervous system (CNS). The incidence of Candida meningitis among infants with candidemia varies from 5% to 25%.3,5,6 Meningitis is not the only manifes- tation of CNS disease; parenchymal abscesses and vasculitis are also frequent in infants with invasive candidiasis.7 Therefore, CNS involvement in invasive candidiasis among infants can best be termed meningoencephalitis. In meningoencephalitis due to Candida, cerebrospinal fluid (CSF) culture results are often negative, CSF parame- ters (eg, white blood cell count) are often normal,5 and imaging is unreliable. Given the high incidence of meningoencephalitis in the setting of candidemia and the lack of reliability of testing, the presence of meningoencephalitis should be assumed in the neonate with candidemia.
    [Show full text]
  • Point Prevalence Survey of Healthcare-Associated Infections and Antimicrobial Use in European Acute Care Hospitals
    TECHNICAL DOCUMENT Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals Protocol version 5.3 www.ecdc.europa.eu ECDC TECHNICAL DOCUMENT Point prevalence survey of healthcare- associated infections and antimicrobial use in European acute care hospitals Protocol version 5.3, ECDC PPS 2016–2017 Suggested citation: European Centre for Disease Prevention and Control. Point prevalence survey of healthcare- associated infections and antimicrobial use in European acute care hospitals – protocol version 5.3. Stockholm: ECDC; 2016. Stockholm, October 2016 ISBN 978-92-9193-993-0 doi 10.2900/374985 TQ-04-16-903-EN-N © European Centre for Disease Prevention and Control, 2016 Reproduction is authorised, provided the source is acknowledged. ii TECHNICAL DOCUMENT PPS of HAIs and antimicrobial use in European acute care hospitals – protocol version 5.3 Contents Abbreviations ............................................................................................................................................... vi Background and changes to the protocol .......................................................................................................... 1 Objectives ..................................................................................................................................................... 3 Inclusion/exclusion criteria .............................................................................................................................. 4 Hospitals .................................................................................................................................................
    [Show full text]